Revitope Oncology
Developing a novel approach to cancer immunotherapy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
$10.0m | Early VC | ||
| Total Funding | 000k | ||
Related Content
Revitope Oncology Inc., based in Cambridge, MA, and Shanghai, China, is pioneering the development of novel T cell engaging antibody circuits (TEAC) and Antibody Peptide Epitope Circuits (APEC) aimed at targeting tumors with high precision. The company operates in the immuno-oncology market, focusing on creating safer, life-changing medicines that restore hope for a healthy future beyond cancer. Revitope's core clients include healthcare providers, research institutions, and pharmaceutical companies seeking advanced cancer treatment solutions. The business model revolves around research and development, clinical trials, and partnerships with other biotech firms to bring their innovative therapies to market. Revenue is generated through licensing agreements, partnerships, and potential future sales of approved therapies.
Keywords: T cell engaging, antibody circuits, immuno-oncology, cancer therapy, TEAC, APEC, tumor targeting, biotech, clinical trials, precision medicine.